had a relapse/inflammation worse; inflammation worse; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-Aug-2022 and was forwarded to Moderna on 25-Aug-2022.    This spontaneous case was reported by a consumer and describes the occurrence of MULTIPLE SCLEROSIS RELAPSE (had a relapse/inflammation worse) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Heat exhaustion (episodes of heat exhaustion), Anxiety, Hot flashes (Menopause Hot Flashes), Gait disturbance, Vehicular accident (Car Accident), Falling, Stress, Fatigue (Exhausion, Worn Out,), Numbness, Dizziness and Wisdom teeth removal. Concurrent medical conditions included MS, Penicillin allergy, Drug allergy (Darvocet Allergy), Allergy to plants (Poison Ivy Reaction), Hypercholesterolemia (cholesterol is high side of normal/ High Cholesterol), Menopause, Dyslexia, Memory disturbance (Poor memory), Weight gain (Putting on Weight), Cane user, Sleepiness (Slept 3 days), Pain, Vomiting (throwing up), Diarrhea, Sweating, Inflammation, COVID-19, Multiple sclerosis relapse (increase in lesions, lost feeling in bottom feet, fall, could not stand, had relapsed-reemitted multiple sclerosis but moved to primary progression.) and Sickness. Concomitant products included ARMODAFINIL (NUVIGIL), SERTRALINE, CALCIUM, COLECALCIFEROL (CALCIUM + D3 [CALCIUM;COLECALCIFEROL]), ATORVASTATIN, MODAFINIL, COLLAGEN, FENUGREEK [TRIGONELLA FOENUM-GRAECUM], ANGELICA SINENSIS ROOT (DONG QUAI [ANGELICA SINENSIS ROOT]), ESTRADIOL, CALCIUM CARBONATE, DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]), CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]), VITAMIN D NOS and VITAMIN K [VITAMIN K NOS] for an unknown indication.   In April 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MULTIPLE SCLEROSIS RELAPSE (had a relapse/inflammation worse) (seriousness criterion medically significant) and CONDITION AGGRAVATED (inflammation worse). At the time of the report, MULTIPLE SCLEROSIS RELAPSE (had a relapse/inflammation worse) and CONDITION AGGRAVATED (inflammation worse) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: cholesterol is high side of normal/ High Cholesterol.         Reported that patient received the Moderna covid vaccination in left arm/shoulder.  No treatment information was provided. Company comment: This spontaneous case concerns a female patient of unknown age with current medical history of Multiple sclerosis, who experienced the unexpected, serious (Medically significant, Hospitalization) AESI of Multiple sclerosis relapse. The exact date of onset of the event was not specified in respect to the administration of first and second dose of mRNA-1273, hence latency could not be assessed. It has been reported that the patient had relapse of Multiple sclerosis after the first dose and after the second dose the patient was hospitalized due to relapse of Multiple sclerosis. Details of concomitant medications, clinical course and treatment were not provided. The outcome of the event is unknown at the time of the report. The patient's medical history of Multiple sclerosis could eb a confounder to the event Multiple sclerosis relapse. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.   This case was linked to MOD-2021-244768 (Patient Link).; Sender's Comments: This spontaneous case concerns a female patient of unknown age with current medical history of Multiple sclerosis, who experienced the unexpected, serious (Medically significant, Hospitalization) AESI of Multiple sclerosis relapse. The exact date of onset of the event was not specified in respect to the administration of first and second dose of mRNA-1273, hence latency could not be assessed. It has been reported that the patient had relapse of Multiple sclerosis after the first dose and after the second dose the patient was hospitalized due to relapse of Multiple sclerosis. Details of concomitant medications, clinical course and treatment were not provided. The outcome of the event is unknown at the time of the report. The patient's medical history of Multiple sclerosis could eb a confounder to the event Multiple sclerosis relapse. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.